share_log

Hainan Haiyao (SZSE:000566) Sheds CN¥363m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Five Years

Hainan Haiyao (SZSE:000566) Sheds CN¥363m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Five Years

海南海藥(深圳證券交易所代碼:000566)下跌3.63億元人民幣,公司收益和投資者回報率在過去五年中一直呈下降趨勢
Simply Wall St ·  04/17 21:39

We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly. For example the Hainan Haiyao Co., Ltd. (SZSE:000566) share price dropped 61% over five years. That's an unpleasant experience for long term holders. We also note that the stock has performed poorly over the last year, with the share price down 33%. Shareholders have had an even rougher run lately, with the share price down 17% in the last 90 days.

我們認爲明智的長期投資是必經之路。但在此過程中,一些股票將表現不佳。例如,海南海藥股份有限公司(深圳證券交易所代碼:000566)的股價在五年內下跌了61%。對於長揸者來說,這是一種不愉快的經歷。我們還注意到,該股去年表現不佳,股價下跌了33%。股東們最近的表現更加艱難,股價在過去90天中下跌了17%。

After losing 7.6% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

在上週下跌7.6%之後,值得研究該公司的基本面,看看我們可以從過去的表現中推斷出什麼。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。

During five years of share price growth, Hainan Haiyao moved from a loss to profitability. Most would consider that to be a good thing, so it's counter-intuitive to see the share price declining. Other metrics may better explain the share price move.

在五年的股價增長中,海南海藥從虧損轉爲盈利。大多數人會認爲這是一件好事,因此股價下跌是違反直覺的。其他指標可以更好地解釋股價走勢。

It could be that the revenue decline of 8.6% per year is viewed as evidence that Hainan Haiyao is shrinking. This has probably encouraged some shareholders to sell down the stock.

每年8.6%的收入下降可能被視爲海南海藥正在萎縮的證據。這可能鼓勵了一些股東拋售該股。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。

earnings-and-revenue-growth
SZSE:000566 Earnings and Revenue Growth April 18th 2024
SZSE: 000566 2024年4月18日收益和收入增長

Take a more thorough look at Hainan Haiyao's financial health with this free report on its balance sheet.

通過這份免費的資產負債表報告,更全面地了解海南海藥的財務狀況。

A Different Perspective

不同的視角

We regret to report that Hainan Haiyao shareholders are down 33% for the year. Unfortunately, that's worse than the broader market decline of 20%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 10% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for Hainan Haiyao that you should be aware of.

我們遺憾地報告,海南海藥股東今年下跌了33%。不幸的是,這比整個市場20%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨10%的總虧損。我們意識到羅斯柴爾德男爵曾說過,投資者應該 “在街頭流血時買入”,但我們警告說,投資者應首先確保他們購買的是高質量的企業。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,我們已經確定了海南海藥的1個警告標誌,你應該注意。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論